We are live on ! Find out more
PAP

Persistent Asset Partners Portfolio holdings

AUM $268M
1-Year Est. Return 158.98%
This Fund
S&P 500
This Quarter Est. Return
+2.11%
1 Year Est. Return
+158.98%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$119M
AUM Growth
-$1.36M
Cap. Flow
+$6.26M
Cap. Flow %
5.25%
Top 10 Hldgs %
39.35%
Holding
221
New
78
Increased
37
Reduced
38
Closed
48

Sector Composition

1 Healthcare 60.53%
2 Financials 20.86%
3 Materials 3.73%
4 Energy 1.78%
5 Industrials 0.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PCVX icon
76
PUT
Vaxcyte
PCVX
$8.12B
$335K 0.28%
+119
New +$9.51K
UWMC icon
77
UWM Holdings
UWMC
$685M
$327K 0.27%
59,814
-2,317
-4% -$14.1K
FLUT icon
78
Flutter Entertainment
FLUT
$18.5B
$325K 0.27%
+1,469
New +$380K
RDDT icon
79
Reddit
RDDT
$34.9B
$315K 0.26%
+3,000
New +$496K
GEV icon
80
GE Vernova
GEV
$284B
$305K 0.26%
+1,000
New +$349K
VTGN icon
81
VistaGen Therapeutics
VTGN
$9.4M
$304K 0.26%
121,651
ASND icon
82
Ascendis Pharma A/S
ASND
$17.1B
$297K 0.25%
1,906
-7,034
-79% -$1M
COOP
83
DELISTED
Mr. Cooper
COOP
$286K 0.24%
2,388
-3,205
-57% -$335K
HCC icon
84
Warrior Met Coal
HCC
$4.17B
$285K 0.24%
+5,978
New +$305K
ORCL icon
85
Oracle
ORCL
$364B
$280K 0.23%
+2,000
New +$326K
RLAY icon
86
Relay Therapeutics
RLAY
$4.34B
$263K 0.22%
100,484
-45,344
-31% -$178K
TRVI icon
87
Trevi Therapeutics
TRVI
$2.71B
$260K 0.22%
+41,404
New +$198K
RARE icon
88
PUT
Ultragenyx Pharmaceutical
RARE
$2.88B
$258K 0.22%
320
MREO
89
Mereo BioPharma
MREO
$49.5M
$255K 0.21%
+113,247
New +$320K
TGB
90
Trekor Metals
TGB
$2.48B
$237K 0.2%
+105,769
New +$224K
APGE icon
91
CALL
Apogee Therapeutics
APGE
$10.1B
$233K 0.2%
293
+239
+443% +$9.24K
GPK icon
92
Graphic Packaging
GPK
$3.2B
$233K 0.2%
8,966
-17,181
-66% -$460K
INTC icon
93
Intel
INTC
$478B
$227K 0.19%
+10,000
New +$219K
ESQ icon
94
Esquire Financial Holdings
ESQ
$1.06B
$227K 0.19%
3,008
+211
+8% +$16.8K
BBIO icon
95
CALL
BridgeBio Pharma
BBIO
$15.9B
$224K 0.19%
303
-269
-47% -$9.07K
PCRX icon
96
Pacira BioSciences
PCRX
$1.01B
$223K 0.19%
+8,963
New +$215K
FCFS icon
97
FirstCash
FCFS
$9.36B
$216K 0.18%
+1,794
New +$203K
LLY icon
98
PUT
Eli Lilly
LLY
$1.05T
$215K 0.18%
+48
New +$39.9K
NBIS
99
Nebius Group N.V.
NBIS
$45.1B
$211K 0.18%
+10,000
New +$329K
URGN icon
100
UroGen Pharma
URGN
$1.96B
$194K 0.16%
+17,571
New +$187K

Similar funds

Persistent Asset Partners's Q1 2025 Portfolio in Review

As of Q1 2025, Persistent Asset Partners held 221 positions worth $119M, down 1.1% from $121M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Persistent Asset Partners deployed $6.26M of net new capital in Q1 2025, opening 78 new positions and adding to 37 existing holdings. Its largest new stake was iShares Bitcoin Trust: 150,623 shares worth $7.05M.

By sector, the portfolio is most concentrated in Healthcare at 61% of assets, down from 68% a quarter earlier, followed by Financials and Materials.

On the sell side, the largest reduction was Humana, an estimated $9.46M trimmed.

  • Persistent Asset Partners's largest Q1 2025 buy was iShares Bitcoin Trust: 150,623 shares worth $7.05M.
  • Persistent Asset Partners added most to Centene in Q1 2025, an estimated $7.51M increase.
  • Persistent Asset Partners's biggest Q1 2025 reduction was Humana, cutting an estimated $9.46M.
  • Persistent Asset Partners fully exited Walgreens Boots Alliance in Q1 2025, selling an estimated $3.51M.
  • Persistent Asset Partners's ten largest holdings make up 39% of its $119M portfolio in Q1 2025.
  • Persistent Asset Partners opened 78 new positions and closed 48 in Q1 2025.
  • Persistent Asset Partners's portfolio value fell 1.1% quarter-over-quarter to $119M.

Based on Persistent Asset Partners's 13F filing for Q1 2025, filed 13 May 2025.